|
KMID : 0939920190510010408
|
|
대한암학회지
2019 Volume.51 No. 1 p.408 ~ p.412
|
|
|
Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
|
|
Lee Ji-Yun
Shim Joon-Ho
Park Woong-Yang
Kim Hee-Kyung
Sun Jong-Mu
Lee Se-Hoon
Ahn Jin-Seok
Park Keun-Chil
Ahn Myung-Ju
|
|
|
Abstract
|
|
|
|
Epidermal growth factor receptor (EGFR)?tyrosine kinase inhibitors (TKIs) are effective clinical therapeutics for EGFR-mutant non-small cell lung cancer (NSCLC). Osimertinib, a thirdgeneration EGFR TKI, has proven effective against T790M mutations. However, the vast majority of patients acquire resistance following successful treatment. A 59-year-old female patient with metastatic NSCLC developed resistance after 43 weeks of osimertinib. CancerSCAN of the metastatic liver lesion revealed a EGFR C797G mutation at an allele frequency of 72%, a preexisting T790M mutation (73%) in cis and an exon 19 deletion (87%). Another 53-year-old female patient developed systemic progression after 10 months of osimertinib. CancerSCAN of the lung biopsy identified an EGFR L718Q mutation at an allele frequency of 7%, concomitant PIK3CA E545K (12.90%) and preexisting EGFR L858R (38%), but loss of the T790M mutation. The heterogeneity of osimertinib resistance mechanisms warrants further investigation into novel or combination agents to overcome the rare acquired resistances.
|
|
|
KEYWORD
|
|
|
Osimertinib, AZD9291, Resistance
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
    
|